OKYO Pharma Limited - נכסים נקיים למניה בודדת OKYO

OKYO Pharma Limited (OKYO) is developing advanced eye drops to combat dry eye by targeting inflammatory neural pathways. The BVPS trend captures actual capital stripped of market noise, with the latest reading standing at 0.24. Steady demand for chronic condition therapies ensures long-term margins. An active pipeline of topical agents and preparations for Phase II trials confirm high growth potential.

Book value per share reflects the portion of equity attributable to a single security and depends directly on the efficiency of net asset accumulation. For OKYO Pharma Limited (OKYO), whose ophthalmological developments are independent of economic cycles, growth in this metric confirms the fundamental resilience of the business, allowing for an assessment of the asset's defensive qualities through the book value per share ratio.